- 関
- ibritumomab tiuxetan
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Radiobiologic optimization of combination radiopharmaceutical therapy applied to myeloablative treatment of non-hodgkin lymphoma.
- Hobbs RF, Wahl RL, Frey EC, Kasamon Y, Song H, Huang P, Jones RJ, Sgouros G.SourceJohns Hopkins University, Baltimore Maryland.
- Journal of nuclear medicine : official publication, Society of Nuclear Medicine.J Nucl Med.2013 Sep;54(9):1535-42. doi: 10.2967/jnumed.112.117952. Epub 2013 Aug 5.
- Combination treatment is a hallmark of cancer therapy. Although the rationale for combination radiopharmaceutical therapy was described in the mid-1990s, such treatment strategies have only been implemented clinically recently and without a rigorous methodology for treatment optimization. Radiobiolo
- PMID 23918734
- DEVELOPMENT OF ANTHROPOMORPHIC HAND PHANTOMS FOR PERSONAL DOSIMETRY IN 90Y-ZEVALIN PREPARATION AND PATIENT DELIVERING.
- Ciolini R, d'Errico F, Traino AC, Paternostro E, Laganà A, Romei C, Pazzagli F, Del Gratta A.SourceDepartment of Civil and Industrial Engineering (DICI), University of Pisa, Largo L. Lazzarino 1, Pisa I-56126, Italy.
- Radiation protection dosimetry.Radiat Prot Dosimetry.2013 Aug 19. [Epub ahead of print]
- Anthropomorphic tissue-equivalent hand phantoms were achieved to measure the extremity dose involved in Zevalin 90Y-labelling and patient delivering procedure for radioimmunotherapy treatment of non-Hodgkin lymphoma. The extremity doses to hands and wrists of operators were measured by using thermol
- PMID 23960242
- Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose 90Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAM.
- Devizzi L, Guidetti A, Seregni E, Passera R, Maccauro M, Magni M, Testi A, Di Nicola M, Tarella C, Matteucci P, Viviani S, Ruella M, Carlo-Stella C, Chiesa C, Cox MC, Bombardieri E, Gianni AM.SourceMedical Oncology; Fondazione IRCCS Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy; lilli.devizzi@istitutotumori.mi.it.
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology.J Clin Oncol.2013 Aug 10;31(23):2974-6. doi: 10.1200/JCO.2013.50.2922. Epub 2013 Jul 15.
- PMID 23857974
Japanese Journal
- 〈Case Reports〉Recognition of complete response by long-term observation after treatment with ^<90>Y-Ibritumomab tiuxetan for relapsed follicular lymphoma
- 放射免疫療法:イットリウム90標識イブリツモマブチウキセタン(90Y-Zevalin)による悪性リンパ腫の治療 (特集 放射線治療の臨床応用)
Related Links
- Zevalin.jp はCD20陽性の再発または難治性の低悪性度B細胞性非ホジキンリンパ腫(NHL)、ならびにマントル細胞リンパ腫(MCL)の治療を目的とした「ゼヴァリン®によるRI標識抗体療法」が安全かつ最大の治療効果を得るべく実施される ...
- Zevalin.jp は「ゼヴァリン®によるRI標識抗体療法」が安全かつ最大の治療効果を得るべく実施されるための様々な情報を提供しています。このページでは医療関係者向けにゼヴァリン療法の概要について説明しています。
Related Pictures